Novo Nordisk more than doubles 2025 obesity sales goal

Novo Nordisk has more than doubled its goal for the sales of its obesity drugs, now aiming for over DKK 25bn (USD 3.7bn) in sales in 2025.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app